Annual FCF
-$16.12 M
+$4.72 M+22.64%
December 31, 2023
Summary
- As of February 7, 2025, CYCC annual free cash flow is -$16.12 million, with the most recent change of +$4.72 million (+22.64%) on December 31, 2023.
- During the last 3 years, CYCC annual FCF has fallen by -$8.09 million (-100.72%).
- CYCC annual FCF is now -139.14% below its all-time high of -$6.74 million, reached on December 31, 2018.
Performance
CYCC Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$3.07 M
+$17.00 K+0.55%
September 30, 2024
Summary
- As of February 7, 2025, CYCC quarterly free cash flow is -$3.07 million, with the most recent change of +$17.00 thousand (+0.55%) on September 30, 2024.
- Over the past year, CYCC quarterly FCF has increased by +$843.00 thousand (+21.56%).
- CYCC quarterly FCF is now -1425.87% below its all-time high of -$201.00 thousand, reached on June 30, 2017.
Performance
CYCC Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$10.54 M
+$969.00 K+8.42%
September 30, 2024
Summary
- As of February 7, 2025, CYCC TTM free cash flow is -$10.54 million, with the most recent change of +$969.00 thousand (+8.42%) on September 30, 2024.
- Over the past year, CYCC TTM FCF has increased by +$5.57 million (+34.58%).
- CYCC TTM FCF is now -181.40% below its all-time high of -$3.75 million, reached on March 31, 2003.
Performance
CYCC TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
CYCC Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.6% | +21.6% | +34.6% |
| 3 y3 years | -100.7% | +55.3% | +49.6% |
| 5 y5 years | -139.1% | +55.3% | +49.6% |
CYCC Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +22.6% | -535.0% | +56.0% | -8.3% | +51.4% |
| 5 y | 5-year | -100.7% | +22.6% | -535.0% | +56.0% | -35.3% | +51.4% |
| alltime | all time | -139.1% | +46.8% | -1425.9% | +69.5% | -181.4% | +66.8% |
Cyclacel Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.07 M(-0.6%) | -$10.54 M(-8.4%) |
| Jun 2024 | - | -$3.08 M(+538.5%) | -$11.51 M(+18.3%) |
| Mar 2024 | - | -$483.00 K(-87.6%) | -$9.73 M(-39.6%) |
| Dec 2023 | -$16.12 M(-22.6%) | -$3.91 M(-3.1%) | -$16.12 M(-7.2%) |
| Sep 2023 | - | -$4.04 M(+209.3%) | -$17.38 M(-14.4%) |
| Jun 2023 | - | -$1.30 M(-81.0%) | -$20.31 M(-2.9%) |
| Mar 2023 | - | -$6.87 M(+32.8%) | -$20.92 M(+0.4%) |
| Dec 2022 | -$20.83 M(+12.2%) | -$5.17 M(-25.8%) | -$20.83 M(+3.1%) |
| Sep 2022 | - | -$6.97 M(+263.3%) | -$20.22 M(+3.8%) |
| Jun 2022 | - | -$1.92 M(-71.7%) | -$19.47 M(-10.3%) |
| Mar 2022 | - | -$6.78 M(+49.0%) | -$21.70 M(+16.9%) |
| Dec 2021 | -$18.57 M(+131.2%) | -$4.55 M(-26.8%) | -$18.57 M(+22.1%) |
| Sep 2021 | - | -$6.22 M(+49.7%) | -$15.21 M(+36.2%) |
| Jun 2021 | - | -$4.15 M(+14.0%) | -$11.17 M(+26.0%) |
| Mar 2021 | - | -$3.64 M(+205.2%) | -$8.86 M(+10.4%) |
| Dec 2020 | -$8.03 M(-15.1%) | -$1.19 M(-45.2%) | -$8.03 M(+0.9%) |
| Sep 2020 | - | -$2.18 M(+18.0%) | -$7.96 M(+2.1%) |
| Jun 2020 | - | -$1.85 M(-34.3%) | -$7.79 M(-9.2%) |
| Mar 2020 | - | -$2.81 M(+151.0%) | -$8.58 M(-9.3%) |
| Dec 2019 | -$9.46 M(+40.3%) | -$1.12 M(-44.4%) | -$9.46 M(-8.9%) |
| Sep 2019 | - | -$2.02 M(-23.6%) | -$10.38 M(+14.2%) |
| Jun 2019 | - | -$2.64 M(-28.5%) | -$9.09 M(+10.0%) |
| Mar 2019 | - | -$3.69 M(+80.5%) | -$8.27 M(+22.6%) |
| Dec 2018 | -$6.74 M(-10.0%) | -$2.04 M(+181.7%) | -$6.74 M(-2.6%) |
| Sep 2018 | - | -$725.00 K(-60.0%) | -$6.92 M(-7.2%) |
| Jun 2018 | - | -$1.81 M(-16.1%) | -$7.45 M(+27.6%) |
| Mar 2018 | - | -$2.16 M(-2.7%) | -$5.84 M(-22.0%) |
| Dec 2017 | -$7.49 M(-25.7%) | -$2.22 M(+76.6%) | -$7.49 M(-8.8%) |
| Sep 2017 | - | -$1.26 M(+525.9%) | -$8.21 M(-17.1%) |
| Jun 2017 | - | -$201.00 K(-94.7%) | -$9.91 M(-7.8%) |
| Mar 2017 | - | -$3.81 M(+29.5%) | -$10.74 M(+6.6%) |
| Dec 2016 | -$10.08 M(-30.4%) | -$2.94 M(-0.3%) | -$10.08 M(+2.7%) |
| Sep 2016 | - | -$2.95 M(+185.0%) | -$9.81 M(-10.6%) |
| Jun 2016 | - | -$1.04 M(-67.1%) | -$10.98 M(-13.8%) |
| Mar 2016 | - | -$3.15 M(+17.5%) | -$12.73 M(-12.2%) |
| Dec 2015 | -$14.49 M(-23.8%) | -$2.68 M(-34.9%) | -$14.49 M(-6.4%) |
| Sep 2015 | - | -$4.12 M(+47.7%) | -$15.49 M(-13.1%) |
| Jun 2015 | - | -$2.79 M(-43.3%) | -$17.82 M(-7.0%) |
| Mar 2015 | - | -$4.91 M(+33.7%) | -$19.17 M(+0.8%) |
| Dec 2014 | -$19.01 M(+3.3%) | -$3.67 M(-43.0%) | -$19.01 M(-8.7%) |
| Sep 2014 | - | -$6.44 M(+55.8%) | -$20.82 M(+26.0%) |
| Jun 2014 | - | -$4.13 M(-13.1%) | -$16.52 M(-6.7%) |
| Mar 2014 | - | -$4.76 M(-13.3%) | -$17.70 M(-3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$18.41 M(+52.7%) | -$5.49 M(+155.7%) | -$18.41 M(+19.7%) |
| Sep 2013 | - | -$2.15 M(-59.6%) | -$15.38 M(+0.2%) |
| Jun 2013 | - | -$5.31 M(-2.7%) | -$15.34 M(+11.7%) |
| Mar 2013 | - | -$5.46 M(+122.0%) | -$13.73 M(+13.9%) |
| Dec 2012 | -$12.05 M(-13.8%) | -$2.46 M(+16.5%) | -$12.05 M(-6.2%) |
| Sep 2012 | - | -$2.11 M(-43.1%) | -$12.86 M(-1.2%) |
| Jun 2012 | - | -$3.71 M(-2.0%) | -$13.01 M(-6.2%) |
| Mar 2012 | - | -$3.78 M(+16.0%) | -$13.87 M(-0.8%) |
| Dec 2011 | -$13.98 M(-12.9%) | -$3.26 M(+43.7%) | -$13.98 M(-3.3%) |
| Sep 2011 | - | -$2.27 M(-50.3%) | -$14.47 M(-1.8%) |
| Jun 2011 | - | -$4.56 M(+17.3%) | -$14.72 M(-2.9%) |
| Mar 2011 | - | -$3.89 M(+4.0%) | -$15.17 M(-5.5%) |
| Dec 2010 | -$16.05 M(+7.7%) | -$3.74 M(+48.1%) | -$16.05 M(+10.1%) |
| Sep 2010 | - | -$2.53 M(-49.6%) | -$14.58 M(+2.4%) |
| Jun 2010 | - | -$5.01 M(+4.9%) | -$14.24 M(-4.3%) |
| Mar 2010 | - | -$4.78 M(+110.4%) | -$14.88 M(-0.1%) |
| Dec 2009 | -$14.90 M(-50.8%) | -$2.27 M(+4.0%) | -$14.90 M(-21.6%) |
| Sep 2009 | - | -$2.18 M(-61.4%) | -$19.02 M(-11.4%) |
| Jun 2009 | - | -$5.65 M(+17.9%) | -$21.45 M(-14.2%) |
| Mar 2009 | - | -$4.79 M(-24.9%) | -$25.00 M(-17.4%) |
| Dec 2008 | -$30.27 M(+21.5%) | -$6.38 M(+38.2%) | -$30.27 M(-0.3%) |
| Sep 2008 | - | -$4.62 M(-49.8%) | -$30.37 M(-4.4%) |
| Jun 2008 | - | -$9.20 M(-8.6%) | -$31.77 M(+10.4%) |
| Mar 2008 | - | -$10.06 M(+55.3%) | -$28.77 M(+15.5%) |
| Dec 2007 | -$24.91 M(+19.5%) | -$6.48 M(+7.7%) | -$24.91 M(+11.4%) |
| Sep 2007 | - | -$6.02 M(-2.9%) | -$22.36 M(-1.7%) |
| Jun 2007 | - | -$6.20 M(-0.0%) | -$22.75 M(-7.7%) |
| Mar 2007 | - | -$6.21 M(+58.1%) | -$24.66 M(+18.3%) |
| Dec 2006 | -$20.84 M(+35.3%) | -$3.92 M(-38.9%) | -$20.84 M(-2.6%) |
| Sep 2006 | - | -$6.42 M(-20.9%) | -$21.39 M(+26.9%) |
| Jun 2006 | - | -$8.11 M(+240.6%) | -$16.85 M(+30.6%) |
| Mar 2006 | - | -$2.38 M(-46.7%) | -$12.90 M(-16.3%) |
| Dec 2005 | -$15.40 M(-39.7%) | -$4.47 M(+137.1%) | -$15.40 M(-19.5%) |
| Sep 2005 | - | -$1.89 M(-54.7%) | -$19.14 M(-23.3%) |
| Jun 2005 | - | -$4.16 M(-14.9%) | -$24.97 M(-5.1%) |
| Mar 2005 | - | -$4.89 M(-40.5%) | -$26.32 M(+3.1%) |
| Dec 2004 | -$25.53 M(+54.9%) | -$8.21 M(+6.4%) | -$25.53 M(+15.3%) |
| Sep 2004 | - | -$7.72 M(+40.2%) | -$22.14 M(+24.3%) |
| Jun 2004 | - | -$5.50 M(+34.1%) | -$17.81 M(+5.8%) |
| Mar 2004 | - | -$4.10 M(-14.8%) | -$16.84 M(+2.2%) |
| Dec 2003 | -$16.48 M | -$4.82 M(+42.1%) | -$16.48 M(+41.3%) |
| Sep 2003 | - | -$3.39 M(-25.1%) | -$11.66 M(+41.0%) |
| Jun 2003 | - | -$4.53 M(+20.8%) | -$8.27 M(+120.8%) |
| Mar 2003 | - | -$3.75 M | -$3.75 M |
FAQ
- What is Cyclacel Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals annual FCF year-on-year change?
- What is Cyclacel Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals quarterly FCF year-on-year change?
- What is Cyclacel Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Cyclacel Pharmaceuticals?
- What is Cyclacel Pharmaceuticals TTM FCF year-on-year change?
What is Cyclacel Pharmaceuticals annual free cash flow?
The current annual FCF of CYCC is -$16.12 M
What is the all time high annual FCF for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high annual free cash flow is -$6.74 M
What is Cyclacel Pharmaceuticals annual FCF year-on-year change?
Over the past year, CYCC annual free cash flow has changed by +$4.72 M (+22.64%)
What is Cyclacel Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of CYCC is -$3.07 M
What is the all time high quarterly FCF for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high quarterly free cash flow is -$201.00 K
What is Cyclacel Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, CYCC quarterly free cash flow has changed by +$843.00 K (+21.56%)
What is Cyclacel Pharmaceuticals TTM free cash flow?
The current TTM FCF of CYCC is -$10.54 M
What is the all time high TTM FCF for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals all-time high TTM free cash flow is -$3.75 M
What is Cyclacel Pharmaceuticals TTM FCF year-on-year change?
Over the past year, CYCC TTM free cash flow has changed by +$5.57 M (+34.58%)